sunepitron has been researched along with naluzotan in 1 studies
| Studies (sunepitron) | Trials (sunepitron) | Recent Studies (post-2010) (sunepitron) | Studies (naluzotan) | Trials (naluzotan) | Recent Studies (post-2010) (naluzotan) |
|---|---|---|---|---|---|
| 10 | 0 | 1 | 8 | 3 | 0 |
| Protein | Taxonomy | sunepitron (IC50) | naluzotan (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, OM; Chen, D; Cheruku, S; Dhanoa, DS; Fichman, M; Heifetz, A; Kauffman, M; Marantz, Y; Mohanty, P; Noiman, S; Nudelman, R; Shacham, S; Sharadendu, A | 1 |
1 other study(ies) available for sunepitron and naluzotan
| Article | Year |
|---|---|
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Binding, Competitive; Biological Availability; Cell Line; Clinical Trials, Phase I as Topic; Dogs; Drug Design; Half-Life; Humans; In Vitro Techniques; Male; Mice; Microsomes, Liver; Models, Molecular; Patch-Clamp Techniques; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Structure-Activity Relationship; Sulfonamides | 2006 |